Mirum gains as Phase 3 LIVMARLI trial meets primary endpoint in liver disease
Phase 3positiveLIVMARLIPositive
AI Analysis
Summary
Mirum Pharmaceuticals announced that its Phase 3 LIVMARLI trial met its primary endpoint in liver disease treatment. The positive trial data represents a significant milestone for the company's drug development program.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Phase 3 LIVMARLI trial met primary endpoint
Importance:8/10
Sentiment:
0.85
Phase 3primary endpoint metliver diseasepositive trial data
Related Companies
Read the original article
Published by yahoo_finance on October 12, 2026 2:00 PM